When the body attacks itself the consequences can be debilitating. Think arthritis.
Now researchers in Seattle are testing whether a blockbuster arthritis drug can take on an even more dangerous disease: diabetes, one of the world’s biggest killers.
Roche Holding AG’s Actemra generates $1.2 billion a year by calming the overzealous defense mechanisms of patients with rheumatoid arthritis.
Help employers find you! Check out all the jobs and post your resume.
